BidaskScore Cuts Rating of ICON (NASDAQ:ICLR) To a Sell

ICON Public Limited Company (NASDAQ:ICLR) Logo

ICON (NASDAQ:ICLR) Receives a Downgrade

BidaskScore cut ICON (NASDAQ:ICLR) shares, lowering their rating to a Sell in a report shared with investors on Friday morning. Trading on the $7.27B market cap ICLR will be interesting to observe today.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Coverage

Among 4 analysts covering Icon (NASDAQ:ICLR), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Icon has $161 highest and $140 lowest target. $151.67’s average target is 12.65% above currents $134.64 stock price. Icon had 6 analyst reports since October 26, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, October 26 by Evercore. Mizuho maintained ICON Public Limited Company (NASDAQ:ICLR) on Thursday, February 21 with “Buy” rating. The stock has “Buy” rating by SunTrust on Monday, February 25. As per Friday, January 25, the company rating was upgraded by Mizuho. The company was maintained on Thursday, February 21 by Barclays Capital.

The stock increased 1.82% or $2.41 during the last trading session, reaching $134.64. About 1.16 million shares traded or 282.39% up from the average. ICON Public Limited Company (NASDAQ:ICLR) has risen 22.37% since March 16, 2018 and is uptrending. It has outperformed by 18.00% the S&P500.

Analysts await ICON Public Limited Company (NASDAQ:ICLR) to report earnings on May, 1. They expect $1.61 earnings per share, up 13.38 % or $0.19 from last year’s $1.42 per share. ICLR’s profit will be $86.90M for 20.91 P/E if the $1.61 EPS becomes a reality. After $1.62 actual earnings per share reported by ICON Public Limited Company for the previous quarter, Wall Street now forecasts -0.62 % negative EPS growth.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company has market cap of $7.27 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It has a 22.86 P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

More notable recent ICON Public Limited Company (NASDAQ:ICLR) news were published by: Bizjournals.com which released: “Portland biotech firm sold to global drug developer – Portland Business Journal” on March 04, 2019, also Businesswire.com with their article: “ICON Reports Fourth Quarter and Full Year 2018 Results – Business Wire” published on February 20, 2019, Globenewswire.com published: “Report: Developing Opportunities within Amazon, Prospect Capital, Alliance Data, Duke Realty, Stellus Capital Investment, and ICON — Future Expectations, Projections Moving into 2019 – GlobeNewswire” on February 27, 2019. More interesting news about ICON Public Limited Company (NASDAQ:ICLR) were released by: Benzinga.com and their article: “Earnings Scheduled For February 20, 2019 – Benzinga” published on February 20, 2019 as well as Benzinga.com‘s news article titled: “10 Biggest Price Target Changes For Thursday – Benzinga” with publication date: February 21, 2019.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.